retatrutide triumph Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial TRIUMPH-4: Retatrutide Beat Every Prediction

More research needs to be done to confirm these benefits in humans

The Journal of clinical and aesthetic dermatology

Thats why so many post-GLP-1 bodies walk in with: Tight neck and jaw(Learn more about jaw pain in my blog: Jaw Clenching & Nervous System Patterns in Los Angeles) Overworked upper ribs and thoracic inlet Shallow, fast breathing even though the abdomen is now smaller This is where the breath and fascia connection becomes central, and where Rolfing Structural Integration helps restore diaphragm mobility and nervous system regulation

In the Phase 2 obesity trial (NCT04667377), mean body-weight loss at week 46 was dose-dependent, reaching approximately 14.9% at the highest 4.8-mg dose versus about 2.8% for placebo, per planned-treatment analysis